Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.700539
Title: Nanomedicines for the treatment of tuberculosis
Author: Donnellan, Samantha Mary Kate
ISNI:       0000 0004 5993 7076
Awarding Body: Heriot-Watt University
Current Institution: Heriot-Watt University
Date of Award: 2016
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
Mycobacterium tuberculosis (Mtb) is the bacterium responsible for the human disease tuberculosis (TB). This study aimed to develop a rapid, low cost assay for screening the anti-mycobacterial properties of new therapies. This assay employed a Green Fluorescent Protein reporter strain of Mycobacteruim avium subspecies paratuberculosis (Map), a pathogenic species causing paratuberculosis in ruminants that can be considered a model for Mtb. Mycobacterial growth over time was monitored by fluorescence, testing new potential therapies including metal and drug nanoparticles (NPs), over a range of concentrations for up to 7 days. The new Map-based assay was sufficiently sensitive to distinguish between the toxicity of different metal/metal oxide NPs, ranked: Ag > Cu(II) O > ZnO. Solid drug NPs (SDNs) of TB antibiotics (rifampicin, isoniazid and pyrazinamide) were compared to conventional antibiotics. SDNs of rifampicin were found to be 100 times more toxic to Map than the conventional antibiotics. Fluorescence microscopy revealed the uptake of SDNs by infected macrophages with possible co-localisation with Map. Pilot data supports the ability of the SDN to kill the intracellular Map. These results support the benefits of nanomedicine and suggest that drug doses could be reduced, if delivered as a nano-formulation.
Supervisor: Stone, Vicki ; Stevenson, Karen Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.700539  DOI: Not available
Share: